Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 6
Submit an article Journal homepage
236
Views
0
CrossRef citations to date
0
Altmetric
Commentary on selected article in this issue

Second cancers in chronic lymphocytic leukemia: growing importance in the era of improved treatment outcomes

Petra LangerbeinsDepartment I of Internal Medicine, Center of Integrated Oncology Cologne–Bonn, University Hospital Cologne, Cologne, GermanyCorrespondence[email protected]
,
Christian MaurerDepartment I of Internal Medicine, Center of Integrated Oncology Cologne–Bonn, University Hospital Cologne, Cologne, Germany
,
Paula CramerDepartment I of Internal Medicine, Center of Integrated Oncology Cologne–Bonn, University Hospital Cologne, Cologne, Germany
,
Barbara EichhorstDepartment I of Internal Medicine, Center of Integrated Oncology Cologne–Bonn, University Hospital Cologne, Cologne, Germany
&
Michael HallekDepartment I of Internal Medicine, Center of Integrated Oncology Cologne–Bonn, University Hospital Cologne, Cologne, Germany
Pages 1575-1576 | Published online: 12 May 2015

References

  • Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009;27:904–910.
  • Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
  • Eichhorst B, Fink AM, Busch R, et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Study Group (GCLLSG). Blood 2013;122(Suppl. 1): Abstract 526.
  • Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002;20:3878–3884.
  • Benjamini O, Jain P, Trinh L, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontlinde fludarabine, cyclphosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma 2015;56:1643–1650.
  • Hamblin TJ. Richter's syndrome—the downside of fludarabine? Leuk Res 2005;29:1103–1104.
  • Langerbeins P, Maurer C, Bahlo J, et al. Second primary malignancies in chronic lymphocytic leukemia: a metaanalysis of four prospective trials of the German CLL Study Group. Hematol Oncol 2013;31(Suppl. 1): Abstract 108.
  • McKenna DB, Stockton D, Brewster DH, et al. Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland. Br J Cancer 2003;88:74–78.
  • Greene MH, Wilson J. Second cancer following lymphatic and hematopoietic cancers in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985;68:191–217.
  • Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010;28: 4935–4944.
  • Hisada M, Biggar RJ, Greene MH, et al. Solid tumors after chronic lymphocytic leukemia. Blood 2001;98:1979–1981.
  • Royle JA, Baade PD, Joske D, et al. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer 2011;105: 1076–1081.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.